|Mr. Pierpaolo Guzzo||CFO & Exec. Chairman||43.93k||N/A||1968|
|Ms. Diana Harbort||CEO, Head of Investor Relations & Exec. Director||665.47k||N/A||1966|
|Mr. Marco Pasero||Chief Operating Officer||N/A||N/A||1966|
|Dr. Luigi Moro||Chief Scientific Officer||N/A||N/A||1951|
|Dr. Alessandro Mazzetti||Chief Medical Officer||N/A||N/A||1952|
|Ms. Martina Cartwright||Sr. Director of Medical Affairs||N/A||N/A||1968|
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. As of December 2, 2021, Cassiopea S.p.A. operates as a subsidiary of Cosmo Pharmaceuticals N.V.
Cassiopea S.p.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.